Related Experiment Video

Updated: Aug 10, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Assessment and management of chronic hepatitis B

Marc G Ghany1, Edward C Doo

  • 1Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B-06, 10 Center Drive, MSC 1800, Bethesda, MD 29892-1800, USA. marcg@bldg10.niddk.nih.gov

Infectious Disease Clinics of North America
|March 11, 2006
PubMed

Insights

Understanding chronic hepatitis B (CHB) natural history is key for liver disease management. Current therapies have moderate efficacy, but new treatments offer promising future options for CHB infection.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) management requires understanding its natural history and clinical patterns.
  • Three recognized patterns include HBeAg-positive CHB, HBeAg-negative CHB, and inactive CHB, each with distinct outcomes.

Purpose of the Study:

  • To review the critical aspects of CHB natural history for effective liver disease management.
  • To evaluate current therapeutic options and discuss future directions in CHB treatment.

Main Methods:

  • Review of clinical patterns, diagnostic criteria for therapy initiation, and current treatment guidelines for CHB.
  • Analysis of approved antiviral agents, their efficacy, limitations, and safety profiles.
  • Discussion of emerging therapeutic agents and their potential based on the HBV life cycle.

Main Results:

  • Therapy candidates for CHB have elevated aminotransferases, high HBV DNA levels, and chronic hepatitis on biopsy, irrespective of HBeAg status.
  • Current approved therapies (IFN-a, lamivudine, adefovir) show moderate efficacy, limited by tolerability, resistance, and long-term safety concerns.
  • HBV genotyping is not indicated for CHB patient management.

Conclusions:

  • Effective CHB management hinges on understanding disease natural history and careful consideration of patient factors and drug safety.
  • Despite limitations of current treatments, the development of novel nucleoside/nucleotide analogs and other agents suggests a promising future for CHB therapy.
  • The ideal CHB therapeutic agent should target all viral replicative stages with minimal toxicity.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...